{
    "xml": "<topic id=\"PHP434\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/esomeprazole\" basename=\"esomeprazole\" title=\"ESOMEPRAZOLE\">\n<title>ESOMEPRAZOLE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_914\" namespace=\"/interactions/list-of-drug-interactions/ulcer-healing-drugs/proton-pump-inhibitors/esomeprazole\">Esomeprazole</xref>\n</p>\n<data name=\"vtmid\">317331009</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_104003650\" title=\"Proton pump inhibitors\">Proton pump inhibitors</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34658\" title=\"PROTON PUMP INHIBITORS\" namespace=\"/drug-classes/proton-pump-inhibitors\">PROTON PUMP INHIBITORS</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP71601\" outputclass=\"indicationsAndDose\" rev=\"1.56\" parent=\"/drugs/esomeprazole\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">NSAID-associated gastric ulcer</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8239;mg once daily for 4&#8211;8 weeks.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8239;mg daily continue until oral administration possible, injection to be given over at least 3 minutes.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of NSAID-associated gastric ulcer in patients with an increased risk of gastroduodenal complications who require continued NSAID treatment</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8239;mg daily.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8239;mg daily continue until oral administration possible, injection to be given over at least 3 minutes.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Gastro-oesophageal reflux disease (in the presence of erosive reflux oesophagitis)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;11 years (body-weight 10&#8211;19 kg)</p>\n<p>10&#8239;mg once daily for 8 weeks.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;11 years (body-weight 20 kg and above)</p>\n<p>10&#8211;20&#8239;mg once daily for 8 weeks.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>Initially 40&#8239;mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist; maintenance 20&#8239;mg daily.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 40&#8239;mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist; maintenance 20&#8239;mg daily.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>40&#8239;mg daily continue until oral administration possible, injection to be given over at least 3 minutes.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Symptomatic treatment of gastro-oesophageal reflux disease (in the absence of oesophagitis)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 1&#8211;11 years (body-weight 10 kg and above)</p>\n<p>10&#8239;mg once daily for up to 8 weeks.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>20&#8239;mg once daily for up to 4 weeks, then 20&#8239;mg daily if required.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8239;mg once daily for up to 4 weeks, then 20&#8239;mg daily if required.</p>\n</li>\n</ul>\n<p outputclass=\"routesOfAdministration\">By intravenous injection or by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8239;mg once daily continue until oral administration possible, injection to be given over at least 3 minutes.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Zollinger&#8211;Ellison syndrome</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 40&#8239;mg twice daily, adjusted according to response; usual dose 80&#8211;160&#8239;mg daily, daily dose above 80mg should be given in 2 divided doses.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Severe peptic ulcer bleeding (following endoscopic treatment)</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">Initially by intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 80&#8239;mg, to be given over 30 minutes, then (by continuous intravenous infusion) 8&#8239;mg/hour for 72 hours, then (by mouth) 40&#8239;mg once daily for 4 weeks.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">\n<ph outputclass=\"organism\">\n<i>Helicobacter pylori</i>\n</ph> eradication in combination with clarithromycin and amoxicillin or metronidazole</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>20&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71460\" outputclass=\"unlicensedUse\" rev=\"1.6\" parent=\"/drugs/esomeprazole\">\n<title>Unlicensed use</title>\n<body>\n<section>\n<sectiondiv>\n<p>Tablets and capsules not licensed for use in children 1&#8211;12 years.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71593\" outputclass=\"interactions\" rev=\"1.6\" parent=\"/drugs/esomeprazole\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (proton pump inhibitors).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71581\" outputclass=\"pregnancy\" parent=\"/drugs/esomeprazole\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71763\" outputclass=\"breastFeeding\" parent=\"/drugs/esomeprazole\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71699\" outputclass=\"hepaticImpairment\" parent=\"/drugs/esomeprazole\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p outputclass=\"specificity\">In adults</p>\n<p>In severe hepatic impairment max. 20&#8239;mg daily.</p>\n<p>Severe peptic ulcer bleeding in severe hepatic impairment, initial intravenous infusion of 80&#8239;mg, then by continuous intravenous infusion, 4&#8239;mg/hour for 72 hours.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">In children</p>\n<p>1&#8211;11 years max. 10&#8239;mg daily in severe impairment.</p>\n<p>12&#8211;18 years max. 20&#8239;mg daily in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71565\" outputclass=\"renalImpairment\" parent=\"/drugs/esomeprazole\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises caution in severe renal insufficiency.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71776\" outputclass=\"directionsForAdministration\" rev=\"1.13\" parent=\"/drugs/esomeprazole\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in adults</p>\n<p>For<i>intravenous infusion</i> (<i>Nexium</i>\n<sup>\n<tm tmtype=\"reg\"/>\n</sup>), give continuously <i>or</i> intermittently in Sodium Chloride 0.9%; reconstitute 40&#8211;80&#8239;mg with up to 100&#8239;ml infusion fluid; for intermittent infusion, give requisite dose over 10&#8211;30 minutes; stable for 12 hours in Sodium Chloride 0.9%.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">intravenous</ph> use in children</p>\n<p>For <i>intravenous infusion</i>, dilute reconstituted solution to a concentration not exceeding 800&#8239;micrograms/mL with Sodium Chloride 0.9%; give over 10&#8211;30 minutes.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use</p>\n<p>Do not chew or crush capsules; swallow whole <i>or</i> mix capsule contents in water and drink within 30 minutes.</p>\n<p>Do not crush or chew tablets; swallow whole <i>or</i> disperse in water and drink within 30 minutes.</p>\n<p>Disperse the contents of each sachet of gastro-resistant granules in approx. 15&#8239;mL water. Stir and leave to thicken for a few minutes; stir again before administration and use within 30 minutes; rinse container with 15&#8239;mL water to obtain full dose.</p>\n<p>For administration through a gastric tube, consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP71573\" outputclass=\"patientAndCarerAdvice\" rev=\"1.10\" parent=\"/drugs/esomeprazole\">\n<title>Patient and carer advice</title>\n<body>\n<section outputclass=\"generalPatientAdvice\">\n<sectiondiv>\n<p outputclass=\"specificity\">With <ph outputclass=\"route\">oral</ph> use</p>\n<p>Counselling on administration of gastro-resistant capsules, tablets, and granules advised.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP434-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/esomeprazole\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75597\" title=\"Gastro-resistant tablet\" namespace=\"/drugs/esomeprazole/gastro-resistant-tablet\">Gastro-resistant tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75908\" title=\"Gastro-resistant capsule\" namespace=\"/drugs/esomeprazole/gastro-resistant-capsule\">Gastro-resistant capsule</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75829\" title=\"Gastro-resistant granules\" namespace=\"/drugs/esomeprazole/gastro-resistant-granules\">Gastro-resistant granules</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75675\" title=\"Powder for solution for injection\" namespace=\"/drugs/esomeprazole/powder-for-solution-for-injection\">Powder for solution for injection</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drug\" href=\"#PHP88005\" namespace=\"/drugs/esomeprazole-with-naproxen\" title=\"ESOMEPRAZOLE WITH NAPROXEN\" count=\"1\" rel=\"backlink\">ESOMEPRAZOLE WITH NAPROXEN</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_914\" namespace=\"/interactions/list-of-drug-interactions/ulcer-healing-drugs/proton-pump-inhibitors/esomeprazole\" title=\"Esomeprazole\" count=\"1\" rel=\"link\">Esomeprazole</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34658\" namespace=\"/drug-classes/proton-pump-inhibitors\" title=\"PROTON PUMP INHIBITORS\" count=\"1\" rel=\"link\">PROTON PUMP INHIBITORS</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75597\" namespace=\"/drugs/esomeprazole/gastro-resistant-tablet\" title=\"Gastro-resistant tablet\" count=\"1\" rel=\"link\">Gastro-resistant tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75908\" namespace=\"/drugs/esomeprazole/gastro-resistant-capsule\" title=\"Gastro-resistant capsule\" count=\"1\" rel=\"link\">Gastro-resistant capsule</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75829\" namespace=\"/drugs/esomeprazole/gastro-resistant-granules\" title=\"Gastro-resistant granules\" count=\"1\" rel=\"link\">Gastro-resistant granules</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP75675\" namespace=\"/drugs/esomeprazole/powder-for-solution-for-injection\" title=\"Powder for solution for injection\" count=\"1\" rel=\"link\">Powder for solution for injection</xref>\n</links>\n</topic>",
    "id": "PHP434",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/esomeprazole",
    "basename": "esomeprazole",
    "title": "ESOMEPRAZOLE",
    "interactants": [
        {
            "id": "bnf_int_914",
            "label": "Esomeprazole"
        }
    ],
    "vtmid": "317331009",
    "drugClassification": [
        "Proton pump inhibitors"
    ],
    "inheritsFromClass": [
        "PROTON PUMP INHIBITORS"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "NSAID-associated gastric ulcer",
                        "html": "NSAID-associated gastric ulcer"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By intravenous injection or by intravenous infusion",
                    "html": "By intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "20 mg once daily for 4&#8211;8 weeks.",
                        "html": "<p>20&#8239;mg once daily for 4&#8211;8 weeks.</p>"
                    },
                    {
                        "textContent": "20 mg daily continue until oral administration possible, injection to be given over at least 3 minutes.",
                        "html": "<p>20&#8239;mg daily continue until oral administration possible, injection to be given over at least 3 minutes.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of NSAID-associated gastric ulcer in patients with an increased risk of gastroduodenal complications who require continued NSAID treatment",
                        "html": "Prophylaxis of NSAID-associated gastric ulcer in patients with an increased risk of gastroduodenal complications who require continued NSAID treatment"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By intravenous injection or by intravenous infusion",
                    "html": "By intravenous injection or by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "20 mg daily.",
                        "html": "<p>20&#8239;mg daily.</p>"
                    },
                    {
                        "textContent": "20 mg daily continue until oral administration possible, injection to be given over at least 3 minutes.",
                        "html": "<p>20&#8239;mg daily continue until oral administration possible, injection to be given over at least 3 minutes.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Gastro-oesophageal reflux disease (in the presence of erosive reflux oesophagitis)",
                        "html": "Gastro-oesophageal reflux disease (in the presence of erosive reflux oesophagitis)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By intravenous injection or by intravenous infusion",
                    "html": "By intravenous injection or by intravenous infusion"
                },
                "child": [
                    {
                        "textContent": "10 mg once daily for 8 weeks.",
                        "html": "<p>10&#8239;mg once daily for 8 weeks.</p>",
                        "ageGroup": "1&#8211;11 years (body-weight 10&#8211;19 kg)"
                    },
                    {
                        "textContent": "10&#8211;20 mg once daily for 8 weeks.",
                        "html": "<p>10&#8211;20&#8239;mg once daily for 8 weeks.</p>",
                        "ageGroup": "1&#8211;11 years (body-weight 20 kg and above)"
                    },
                    {
                        "textContent": "Initially 40 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist; maintenance 20 mg daily.",
                        "html": "<p>Initially 40&#8239;mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist; maintenance 20&#8239;mg daily.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 40 mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist; maintenance 20 mg daily.",
                        "html": "<p>Initially 40&#8239;mg once daily for 4 weeks, continued for further 4 weeks if not fully healed or symptoms persist; maintenance 20&#8239;mg daily.</p>"
                    },
                    {
                        "textContent": "40 mg daily continue until oral administration possible, injection to be given over at least 3 minutes.",
                        "html": "<p>40&#8239;mg daily continue until oral administration possible, injection to be given over at least 3 minutes.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Symptomatic treatment of gastro-oesophageal reflux disease (in the absence of oesophagitis)",
                        "html": "Symptomatic treatment of gastro-oesophageal reflux disease (in the absence of oesophagitis)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous injection or intravenous infusion"
                    ],
                    "textContent": "By intravenous injection or by intravenous infusion",
                    "html": "By intravenous injection or by intravenous infusion"
                },
                "child": [
                    {
                        "textContent": "10 mg once daily for up to 8 weeks.",
                        "html": "<p>10&#8239;mg once daily for up to 8 weeks.</p>",
                        "ageGroup": "1&#8211;11 years (body-weight 10 kg and above)"
                    },
                    {
                        "textContent": "20 mg once daily for up to 4 weeks, then 20 mg daily if required.",
                        "html": "<p>20&#8239;mg once daily for up to 4 weeks, then 20&#8239;mg daily if required.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "20 mg once daily for up to 4 weeks, then 20 mg daily if required.",
                        "html": "<p>20&#8239;mg once daily for up to 4 weeks, then 20&#8239;mg daily if required.</p>"
                    },
                    {
                        "textContent": "20 mg once daily continue until oral administration possible, injection to be given over at least 3 minutes.",
                        "html": "<p>20&#8239;mg once daily continue until oral administration possible, injection to be given over at least 3 minutes.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Zollinger&#8211;Ellison syndrome",
                        "html": "Zollinger&#8211;Ellison syndrome"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 40 mg twice daily, adjusted according to response; usual dose 80&#8211;160 mg daily, daily dose above 80mg should be given in 2 divided doses.",
                        "html": "<p>Initially 40&#8239;mg twice daily, adjusted according to response; usual dose 80&#8211;160&#8239;mg daily, daily dose above 80mg should be given in 2 divided doses.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Severe peptic ulcer bleeding (following endoscopic treatment)",
                        "html": "Severe peptic ulcer bleeding (following endoscopic treatment)"
                    }
                ],
                "specificity": {
                    "routes": [
                        "Initially intravenous infusion"
                    ],
                    "textContent": "Initially by intravenous infusion",
                    "html": "Initially by intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "Initially 80 mg, to be given over 30 minutes, then (by continuous intravenous infusion) 8 mg/hour for 72 hours, then (by mouth) 40 mg once daily for 4 weeks.",
                        "html": "<p>Initially 80&#8239;mg, to be given over 30 minutes, then (by continuous intravenous infusion) 8&#8239;mg/hour for 72 hours, then (by mouth) 40&#8239;mg once daily for 4 weeks.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Helicobacter pylori eradication in combination with clarithromycin and amoxicillin or metronidazole",
                        "html": "<ph outputclass=\"organism\"> <i>Helicobacter pylori</i> </ph> eradication in combination with clarithromycin and amoxicillin or metronidazole",
                        "organism": "Helicobacter pylori"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth",
                    "organism": "Helicobacter pylori"
                },
                "adult": [
                    {
                        "textContent": "20 mg twice daily.",
                        "html": "<p>20&#8239;mg twice daily.</p>"
                    }
                ]
            }
        ]
    },
    "unlicensedUse": {
        "unlicensedUse": [
            {
                "type": "unlicensedUse",
                "textContent": "Tablets and capsules not licensed for use in children 1&#8211;12 years.",
                "html": "<p>Tablets and capsules not licensed for use in children 1&#8211;12 years.</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (proton pump inhibitors).",
                "html": "<p>Appendix 1 (proton pump inhibitors).</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution&#8212;no information available.",
                "html": "<p>Manufacturer advises caution&#8212;no information available.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "specificity": {
                    "textContent": "In adults",
                    "html": "In adults",
                    "patientType": "adults"
                },
                "textContent": "In severe hepatic impairment max. 20 mg daily.\n\nSevere peptic ulcer bleeding in severe hepatic impairment, initial intravenous infusion of 80 mg, then by continuous intravenous infusion, 4 mg/hour for 72 hours.",
                "html": "<p>In severe hepatic impairment max. 20&#8239;mg daily.</p><p>Severe peptic ulcer bleeding in severe hepatic impairment, initial intravenous infusion of 80&#8239;mg, then by continuous intravenous infusion, 4&#8239;mg/hour for 72 hours.</p>"
            },
            {
                "type": "doseAdjustments",
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "textContent": "1&#8211;11 years max. 10 mg daily in severe impairment.\n\n12&#8211;18 years max. 20 mg daily in severe impairment.",
                "html": "<p>1&#8211;11 years max. 10&#8239;mg daily in severe impairment.</p><p>12&#8211;18 years max. 20&#8239;mg daily in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises caution in severe renal insufficiency.",
                "html": "<p>Manufacturer advises caution in severe renal insufficiency.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in adults",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in adults",
                    "patientType": "adults",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "Forintravenous infusion (Nexium ), give continuously or intermittently in Sodium Chloride 0.9%; reconstitute 40&#8211;80 mg with up to 100 ml infusion fluid; for intermittent infusion, give requisite dose over 10&#8211;30 minutes; stable for 12 hours in Sodium Chloride 0.9%.",
                "html": "<p>For<i>intravenous infusion</i> (<i>Nexium</i>\n<sup>\n<tm tmtype=\"reg\"/>\n</sup>), give continuously <i>or</i> intermittently in Sodium Chloride 0.9%; reconstitute 40&#8211;80&#8239;mg with up to 100&#8239;ml infusion fluid; for intermittent infusion, give requisite dose over 10&#8211;30 minutes; stable for 12 hours in Sodium Chloride 0.9%.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With intravenous use in children",
                    "html": "With <ph outputclass=\"route\">intravenous</ph> use in children",
                    "patientType": "children",
                    "routes": [
                        "intravenous"
                    ]
                },
                "textContent": "For intravenous infusion, dilute reconstituted solution to a concentration not exceeding 800 micrograms/mL with Sodium Chloride 0.9%; give over 10&#8211;30 minutes.",
                "html": "<p>For <i>intravenous infusion</i>, dilute reconstituted solution to a concentration not exceeding 800&#8239;micrograms/mL with Sodium Chloride 0.9%; give over 10&#8211;30 minutes.</p>"
            },
            {
                "type": "directionsForAdministration",
                "specificity": {
                    "textContent": "With oral use",
                    "html": "With <ph outputclass=\"route\">oral</ph> use",
                    "routes": [
                        "oral"
                    ]
                },
                "textContent": "Do not chew or crush capsules; swallow whole or mix capsule contents in water and drink within 30 minutes.\n\nDo not crush or chew tablets; swallow whole or disperse in water and drink within 30 minutes.\n\nDisperse the contents of each sachet of gastro-resistant granules in approx. 15 mL water. Stir and leave to thicken for a few minutes; stir again before administration and use within 30 minutes; rinse container with 15 mL water to obtain full dose.\n\nFor administration through a gastric tube, consult product literature.",
                "html": "<p>Do not chew or crush capsules; swallow whole <i>or</i> mix capsule contents in water and drink within 30 minutes.</p><p>Do not crush or chew tablets; swallow whole <i>or</i> disperse in water and drink within 30 minutes.</p><p>Disperse the contents of each sachet of gastro-resistant granules in approx. 15&#8239;mL water. Stir and leave to thicken for a few minutes; stir again before administration and use within 30 minutes; rinse container with 15&#8239;mL water to obtain full dose.</p><p>For administration through a gastric tube, consult product literature.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "specificity": {
                    "textContent": "With oral use",
                    "html": "With <ph outputclass=\"route\">oral</ph> use",
                    "routes": [
                        "oral"
                    ]
                },
                "textContent": "Counselling on administration of gastro-resistant capsules, tablets, and granules advised.",
                "html": "<p>Counselling on administration of gastro-resistant capsules, tablets, and granules advised.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP75597",
                "label": "Gastro-resistant tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75908",
                "label": "Gastro-resistant capsule",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75829",
                "label": "Gastro-resistant granules",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75675",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drug": [
            {
                "id": "PHP88005",
                "label": "ESOMEPRAZOLE WITH NAPROXEN",
                "type": "drug"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_914",
                "label": "Esomeprazole",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34658",
                "label": "PROTON PUMP INHIBITORS",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP75597",
                "label": "Gastro-resistant tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75908",
                "label": "Gastro-resistant capsule",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75829",
                "label": "Gastro-resistant granules",
                "type": "medicinalForm"
            },
            {
                "id": "PHP75675",
                "label": "Powder for solution for injection",
                "type": "medicinalForm"
            }
        ]
    }
}